<?xml-stylesheet type="text/xsl" href="https://emersonexchange365.com/cfs-file/__key/system/syndication/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Reducing Execution Errors in Cell Therapeutics Manufacturing</title><link>/community-hubs/deltav-community-connect/b/ops-weblog/posts/reducing-execution-errors-in-cell-therapeutics-manufacturing-1315180906</link><description>In an earlier post, Managing the Chain of Identity in Cell Therapeutics Manufacturing , we highlighted how the manufacturing process of these cell therapies must be performed with absolute accuracy the first time since each batch is produced for a specific</description><dc:language>en-US</dc:language><generator>Telligent Community 13</generator></channel></rss>